November 2, 2023 – Life sciences-focused search firm Slone Partners has recruited Jeremy Bender, Teresa Bitetti, and David Meek as members of the board of directors at Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. “Jeremy Bender, Teresa Bitetti, and David Meek are all very accomplished and highly respected leaders in the fields of biopharmaceuticals, oncology, and therapeutics,” said Leslie Loveless, CEO of Slone Partners. “They bring extraordinary business and scientific experience and knowledge to the board at a very exciting time in the company’s history.”
“We are excited to welcome Jeremy, Teresa, and David to Fusion’s board of directors, each bringing an exceptional breadth of experience and track record of success in oncology drug development, business development, and commercialization,” said John Valliant, CEO of Fusion. “Their experiences introducing innovative therapies to cancer patients as leaders of top-tier oncology companies will be invaluable as we advance our pipeline, particularly our lead program FPI-2265, which is on track to be the first actinium-based PSMA targeted alpha therapy (TAT) to market. Fusion is undergoing an exciting evolution to a later stage radiopharmaceutical company and with these appointments we are transforming our Board to maximize the value generation of our strategy.”
Dr. Bender currently serves as CEO of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on pediatric cancer. Previously, he served as vice president of corporate development at Gilead Sciences, overseeing acquisitions, partnerships, and investments. Dr. Bender also served as CEO at Tizona Therapeutics, chief business officer at Sutro Biopharma, and vice president of corporate development at Allos Therapeutics. He currently sits on the board of Mereo BioPharma as an independent board member.
Ms. Bitetti currently serves as president of the global oncology business unit of Takeda. Previously, she held various roles of increasing responsibility at Bristol-Myers Squibb Company, including as senior vice president, head of worldwide oncology commercialization. At BMS, Ms. Bitetti also served as senior vice president and head of the U.S. oncology business, president and general manager of BMS Canada, and worldwide head of the BMS virology business. She currently serves on the board of Osmol Therapeutics as an independent director.
Mr. Meek most recently served as CEO and member of the board of directors of Mirati Therapeutics. Prior to this role, he served as the president, CEO, and board member of FerGene, and CEO and board member of Ipsen. Mr. Meek was previously an executive vice president and president of oncology at Baxalta Incorporated in the leadup to the acquisition by Shire, and chief commercial officer of Endocyte. He previously held executive leadership roles at Novartis Pharmaceuticals Corporation and Novartis Oncology. Mr. Meek previously served on the board of directors of Entasis Therapeutics (acquired by Innoviva) and currently serves on the board of directors of uniQure N.V.
Life Sciences Specialists
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.
Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Executive Editor; Lily Fauver, Senior Editor – Hunt Scanlon Media